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Intestinal PPARδ protects against 
diet-induced obesity, insulin 
resistance and dyslipidemia
Marcela Doktorova1, Irene Zwarts1, Tim van Zutphen1, Theo H. van Dijk2, Vincent W. Bloks1, 
Liesbeth Harkema3, Alain de Bruin1,3, Michael Downes4, Ronald M. Evans4, Henkjan J. 
Verkade1 & Johan W. Jonker1
Peroxisome proliferator-activated receptor δ (PPARδ) is a ligand-activated transcription factor that 
has an important role in lipid metabolism. Activation of PPARδ stimulates fatty acid oxidation in 
adipose tissue and skeletal muscle and improves dyslipidemia in mice and humans. PPARδ is highly 
expressed in the intestinal tract but its physiological function in this organ is not known. Using mice 
with an intestinal epithelial cell-specific deletion of PPARδ, we show that intestinal PPARδ protects 
against diet-induced obesity, insulin resistance and dyslipidemia. Furthermore, absence of intestinal 
PPARδ abolished the ability of PPARδ agonist GW501516 to increase plasma levels of HDL-cholesterol. 
Together, our findings show that intestinal PPARδ is important in maintaining metabolic homeostasis 
and suggest that intestinal-specific activation of PPARδ could be a therapeutic approach for treatment 
of the metabolic syndrome and dyslipidemia, while avoiding systemic toxicity.
The prevalence of obesity and related chronic metabolic diseases such as type 2 diabetes, cardiovascular disease 
and certain types of cancer is increasing worldwide at an alarming rate. Peroxisome proliferator-activated recep-
tors (PPARs) have emerged as key targets for the treatment of these disorders. PPARs constitute a subfamily 
of the nuclear receptor family of ligand-activated transcription factors. This subfamily consists of three mem-
bers, PPARα, -β/δ and –γ (NR1C1–3), which are activated by (dietary) lipids, specifically polyunsaturated fatty 
acids, and have critical functions in lipid metabolism1. PPARs are also potent regulators of the inflammatory and 
immune response by antagonizing the activities of other transcription factors such as members of the nuclear 
factor-κB (NF-κB) and activator protein-1 (AP-1) families, a process which is named trans-repression2. PPARα 
is the molecular target of the fibrate class of lipid-lowering drugs and is primarily expressed in tissues with a high 
level of fatty acid catabolism such as liver, brown fat, kidney, heart and skeletal muscle where it regulates fatty acid 
oxidation and apolipoprotein synthesis3–5. PPARγ is the molecular target of the thiazolidinedione (TZD) class of 
insulin-sensitizing drugs and is essential for adipocyte differentiation and fat storage6.
PPARδ (also known as PPARβ) is ubiquitously expressed and when activated it promotes fatty acid oxidation, 
thermogenesis, insulin sensitivity, high density lipoprotein cholesterol (HDLc) levels in plasma and overall energy 
expenditure7. PPARδ deficient mice are prone to obesity and insulin resistance when challenged with a high-fat 
diet (HFD). Conversely, transgenic expression of a constitutively active form of PPARδ in adipose tissue or skel-
etal muscle protects mice from diet-induced obesity and regulates muscle fiber type switching, respectively8, 9.
Treatment of mice with the high-affinity PPARδ agonist GW501516 increases plasma levels of HDLc and 
reduces lesion progression in mouse models of atherosclerosis10, 11. In obese rhesus monkeys and healthy humans 
PPARδ agonist administration also increases plasma levels of HDLc and decreases low density lipoprotein choles-
terol (LDLc) and triglycerides (TGs)12, 13. In addition, PPARδ agonists act as exercise mimetics by transcriptional 
remodeling of skeletal muscle resulting in oxidative fiber type switch and improved running endurance14. Based 
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on these findings a number of small molecule PPARδ agonists, including MBX-8025 (Metabolex) and KD3010 
(Kalypsys) are currently under evaluation in clinical trials for dyslipidemia and other aspects of the metabolic 
syndrome7, 15, 16. However, adverse effects, such as the potency of GW501516 to induce cancer in rodent models, 
and widespread abuse by athletes have complicated their progression into the clinic17.
Although PPARδ is abundantly expressed along the entire intestinal tract, its potential role in energy homeo-
stasis in this organ has not been well explored18. Daoudi et al. showed a role of intestinal PPARδ in the stimulation 
of post-prandial glucagon-like protein-1 (GLP1) production in enteroendocrine L-cells, resulting in preservation 
of β-cell morphology and function and, thereby, increased systemic insulin sensitivity19. In the present study 
we evaluated a possible role of PPARδ in the intestine in energy metabolism and the development of metabolic 
syndrome using mice with an intestinal epithelial specific deletion of the PPARδ gene. Here we show that intes-
tinal PPARδ contributes to the protection against diet-induced obesity and that intestinal PPARδ is required for 
mediating the increase in plasma levels of HDLc by PPARδ activation. Together, these results suggest targeting 
of intestinal PPARδ as a potential approach for the therapeutic treatment of dyslipidemia, obesity and insulin 
resistance, with limited systemic toxicity.
Results
Characterization of intestinal epithelial cell (IEC) specific PPARδ knockout (PPARδIEC-KO) 
mice. Mice with an intestinal epithelial cell (IEC) specific deletion of PPARδ were generated by cross-breeding 
mice carrying loxP sites on either side of exon 4 of the PPARδ gene (PPARδlox/lox) with transgenic mice expressing 
Cre recombinase under the control of the IEC-specific villin promoter. Expression of Cre recombinase mRNA 
was specifically localized to the intestine and absent in the liver of PPARδIEC-KO mice (Fig. 1A). Absence of PPARδ 
mRNA in small intestinal mucosa was confirmed by qPCR using primers detecting exon 4 of PPARδ (Fig. 1B). 
Under standard housing conditions PPARδIEC-KO mice displayed no obvious phenotype. They were born at the 
expected Mendelian ratio, and there were no differences in food intake, body weight, liver weight and plasma and 
hepatic lipid composition as compared to their wild-type littermates (Table 1). Also, no differences were observed 
in dietary fat absorption and fecal excretion of neutral sterols (NS) and bile acids (BA) (Fig. 1C,D).
Histopathologic examination of the small intestine (proximal, middle and distal part) revealed no differences 
in villus length, crypt depth and inflammation scoring between wild-type and PPARδIEC-KO mice. We found a 
reduction in the number of Paneth cells, specialized crypt cells involved in immunity and production of antimi-
crobial compounds, in all three sections of the small intestine of PPARδIEC-KO mice, although this did not reach 
statistical significance (median 1.5 [0.5–3.0] vs 2.0 [1.0–3.0], p = 0.13). This observation is in line with a previous 
study that reported a role for PPARδ in the regulation of Paneth cell differentiation through hedgehog signaling, 
using whole body PPARδ knockout mice20. The latter study also reported changes in the microbial composition, 
Figure 1. Characterization of mice with an intestinal epithelial specific deletion of the PPARδ gene 
(PPARδIEC-KO). mRNA levels of (A) Cre recombinase and (B) PPARδ in mucosal scrapings from the small 
intestine (normalized to 36b4); ND = not detectable; (C) Fat balance (% of dietary fat absorption) in mice on a 
LFD and HFD (45% energy content in fat); (D) Fecal excretion of neutral sterols (NS) and bile acids (BA); (E) 
Total bacterial counts in the distal part of the intestine (in intestinal content and mucosa combined) in wild-
type and PPARδIEC-KO mice (n = 7–9).
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with a decrease in Lactobacilli and an increase in Bifidobacteria20. In the current study, however, we did not 
find any differences in Lactobacilli, Eubacteria or total number of bacteria in the middle and distal part of the 
small intestine (Fig. 1E, Supplementary Fig. 1), cecum, colon and feces (data not shown) between wild-type and 
PPARδIEC-KO mice.
Intestinal PPARδ protects against diet-induced obesity and insulin resistance. To determine 
the role of intestinal PPARδ in the development of metabolic syndrome we challenged PPARδIEC-KO mice and 
wild-type littermates for 10 wks with a HFD consisting of 60% kcal from fat. Whereas body weight gain during 10 
wks on a control low-fat diet (LFD, 10% kcal from fat) was not different between genotypes, PPARδIEC-KO displayed 
an increased body weight gain in response to HFD as compared to their wild-type littermates (Fig. 2A,B). Further 
analysis revealed a significant increase was in the amount of omental white adipose tissue (oWAT) in PPARδIEC-KO 
mice as compared to their wild-type littermates, whereas the weight of epididymal and subcutaneous WAT depots 
were not different between genotypes. Although liver weight (Fig. 2C) or liver weight as % of body weight (LW%) 
(Fig. 2D) and TG content (Table 2) were not different, NAFLD activity score (NAS) based on histological anal-
ysis of Hematoxylin & Eosin (H&E) stained liver sections, was significantly increased in PPARδIEC-KO mice from 
1.0 ± 1.3 to 2.9 ± 1.6 (P < 0.05) as compared to wild-type littermates, respectively (Fig. 2C–E, Supplementary 
Fig. 2A,B, Supplementary Table 2). PPARδIEC-KO mice on a HFD displayed significantly increased levels of fasting 
plasma insulin and increased insulin resistance as compared to their wild-type littermates (Fig. 2G,H,J). Fasting 
plasma glucose levels and oral glucose tolerance on the other hand were not different (Fig. 2F,I). In addition, 
no differences were observed in food intake, respiratory exchange rate (RER), activity (Table 2, Supplementary 
Fig. 2C,D) and microbiota in the distal part of the small intestine (data not shown).
PPARδIEC-KO mice challenged with a HFD displayed increased plasma levels of total cholesterol (Table 2). 
Further analysis by fast protein liquid chromatography (FPLC) confirmed increased levels of total cholesterol in 
PPARδIEC-KO mice and showed that this was mainly due to higher levels of LDLc. This difference in lipoprotein pro-
file was not seen on a control LFD (Fig. 3A,B). Levels of proglucagon mRNA in the distal small intestine were sig-
nificantly increased by a HFD in wild-type mice but not in PPARδIEC-KO mice. However, this difference in mRNA 
did not result in reduced plasma levels of GLP-1 in PPARδIEC-KO mice at 30 min after a glucose bolus (Fig. 3C,D). 
Also, no changes in the expression of genes involved in cholesterol transport and the pro-inflammatory cytokine 
TNFα were observed in the distal small intestine of PPARδIEC-KO mice and wild-type littermates challenged with a 
HFD (Fig. 3E,F). Together, these results show that intestinal PPARδ protects against HFD induced obesity, insulin 
resistance and dyslipidemia.
Role of intestinal PPARδ in the response to treatment with the PPARδ agonist GW501516. To 
determine the contribution of intestinal PPARδ to the response to treatment with a PPARδ-specific agonist, 
wild-type and PPARδIEC-KO mice were orally treated for 14 days with GW501516 (3 mg/kg) or vehicle. As pre-
viously reported, liver weight was significantly increased by GW50151621, 22. However, this increase was also 
observed in PPARδIEC-KO mice, suggesting that this effect was independent of intestinal specific activation of 
PPARδ (Table 1). No effect of GW501516 was observed on food intake, body weight, hepatic lipid composition 
and microbiota in the distal part of the small intestine in PPARδIEC-KO mice as compared to their wild-type litter-










(g/24 h) 3.6 ± 0.5 3.8 ± 0.6 3.9 ± 1.1 3.7 ± 1.1
Body weight 
(g) 26.5 ± 2.2 25.9 ± 2.6 26.2 ± 1.3 25.0 ± 1.8
Liver weight 
(% of body 
weight)




4.2 ± 0.2 4.0 ± 0.3 4.0 ± 0.3 4.1 ± 0.1
Liver TG 




17.3 ± 1.1 17.3 ± 1.0 16.9 ± 1.0 17.8 ± 0.5
Plasma TG 




3.5 ± 1.0 3.5 ± 0.9 4.7 ± 0.6 4.1 ± 0.4
Table 1. Animal characteristics and liver composition of wild-type and PPARδIEC-KO mice with and without 
GW501516 treatment on low fat diet. ***Significantly different from wild-type (p < 0.001); ###Significantly 
different from PPARδIEC-KO (p < 0.001); Values are presented as means ± SD (n = 6–7).
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Figure 2. Effect of a HFD on diet-induced obesity, hepatic steatosis and insulin sensitivity in PPARδIEC-KO 
and wild-type mice. Effect of a HFD challenge on (A) Body weight; (B) Body weight gain; (C) Liver and white 
adipose tissue (WAT) (epididymal, omental and subcutaneous) weights; (D) Liver weight as % of body weight; 
(E) NAFLD activity score (NAS score); (F) Fasting blood glucose; (G) Fasting blood insulin; (H) Glucose 
stimulated insulin secretion (GSIS, 2 g/kg p.o. glucose); (I) Oral glucose tolerance test (OGTT, 2 g/kg p.o. 
glucose), graph insert showing area under the curve (AUC); (J) Insulin tolerance test (ITT, graph insert showing 
AUC, in PPARδIEC-KO mice and wild-type littermates (n = 7–10).
www.nature.com/scientificreports/
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Intestinal PPARδ is required for the increase in plasma HDLc by GW501516. Previously, it has 
been reported that small molecule agonists of PPARδ can effectively increase plasma levels of HDLc in rodents, 
primates and humans12, 23, 24. It remains unclear, however, to what extent the intestine contributes to this effect. 
FPLC analysis showed that plasma levels of HDLc were increased by approximately 50% by GW501516 treatment 
in wild-type mice but not in PPARδIEC-KO mice (Fig. 4A,B). This finding was supported by biochemical analysis of 
plasma, showing significantly elevated plasma levels of HDLc by GW501516 treatment in wild-type mice but not 
in PPARδIEC-KO mice (Fig. 4C). In line with earlier findings, the excretion of neutral sterols in the feces was signifi-
cantly increased by GW501516 in wild-type mice and this effect was not observed in PPARδIEC-KO mice, indicating 
that activation of intestinal PPARδ is required for the fecal excretion of neutral sterols (Fig. 4D). GW501516 treat-
ment increased the mRNA levels of the known PPARδ targets Abca1, Apoa1 and Pdk4 in the mucosa of the small 
intestine in wild-type mice but not in PPARδIEC-KO mice (Fig. 4E,F). The expression of other genes involved in cho-
lesterol transport such as Abcg5 and Npc1l1 and pro-inflammatory cytokine Tnf were not changed by GW501516 
treatment in wild-type and PPARδIEC-KO mice (Fig. 4E,F). Together these findings indicate that intestinal PPARδ is 
required for the increase in plasma levels of HDLc by PPARδ agonist treatment, whereas PPARδ elsewhere in the 
body does not significantly contribute to this effect.
Discussion
In this study we investigated the role of intestinal PPARδ in energy metabolism and the development of meta-
bolic syndrome using mice with an intestinal epithelial cell (IEC) specific deletion of PPARδ. Similar mice have 
previously been described and were shown to have a reduced incidence of azoxymethane-induced colon tum-
ors25. Here we show that PPARδIEC-KO mice display increased sensitivity to diet induced obesity and are unable 
to increase plasma HDLc levels after stimulation with the PPARδ specific agonist GW501516, indicating that 
intestinal PPARδ has an important role in the regulation of energy metabolism that cannot be compensated by 
PPARδ activation in other tissues.
The role of PPARδ in the intestine has mostly been studied for its anti-inflammatory effects and in the devel-
opment of colorectal cancer (CRC)26, 27. PPARδ was originally implicated in CRC by its identification as a target 
of the adenomatous polyposis coli (APC) tumor suppressor, a key mediator in the development of CRC28. PPARδ 
expression is elevated in CRCs with a loss of function in the APC pathway and is repressed by expression of APC 
in CRC cells28, 29. Several studies using Apcmin mice or chemically induced CRC have produced conflicting find-
ings and currently there is no consensus on the role of PPARδ in in the development of CRC29.
Two independent whole body PPARδ knockout mouse models have been described30, 31. Both PPARδ knock-
out mouse models displayed an increased embryonic lethality due to a placental defect whereas surviving knock-
out animals were smaller and had reduced adiposity, especially at young age. Older, weight normalized PPARδ 
knockout mice, were found to display decreased metabolic activity and glucose intolerance when fed with a 
standard chow diet32. Contradicting results have been published on PPARδ whole body knockout mice challenged 
with a HFD, showing either increased obesity33 or a similar body weight gain but exaggerated glucose intoler-
ance32. In the current study we found that PPARδIEC-KO mice display increased sensitivity to diet-induced obesity 
and metabolic dysfunction characterized by insulin resistance and increased LDLc plasma levels.
The underlying mechanism by which intestinal PPARδ mediates its metabolic effects remains unclear since 
we did not find changes in food intake, activity or energy expenditure between wild-type and PPARδIEC-KO 
mice. Previously, it has been shown that intestinal PPARδ plays a role in the stimulation of GLP-1 production 
in enteroendocrine L-cells, important for the preservation of β-cell morphology and function and, thereby, 










(g/24 h) 2.8 ± 0.6 2.3 ± 0.6 2.7 ± 0.5 2.9 ± 0.5
Body weight 
(g) 30.0 ± 2.1 29.2 ± 3.1 39.1 ± 4.3 44.4 ± 6.2
Liver weight (% 
of body weight) 3.6 ± 0.3 2.9 ± 0.5 2.6 ± 0.6




6.0 ± 2.3 5.2 ± 0.6 6.4 ± 1.3 5.1 ± 2.0
Liver TG 




26.6 ± 1.6 25.0 ± 0.6 27.9 ± 2.1 26.7 ± 2.8
Plasma TG 




3.3 ± 0.3 2.6 ± 0.9 4.2 ± 0.6 5.0 ± 0.7###
Table 2. Animal characteristics and liver composition of wild-type and PPARδIEC-KO mice after a LFD (n = 3–8) 
or HFD (n = 4–10). *Significantly different from wild-type on LFD (p < 0.05); ###Significantly different from 
PPARδIEC-KO on LFD (p < 0.001). Values are presented as means ± SD.
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mRNA by a HFD was dependent on intestinal PPARδ. It remains unclear, however, whether a deficiency in the 
induction of GLP-1 in PPARδIEC-KO mice contributes to the observed metabolic phenotype since plasma levels of 
GLP-1 after a glucose bolus were not affected by intestinal PPARδ. In addition to GLP-1, proglucagon mRNA pro-
cessing in intestinal L-cells produces several other glucagon-related peptides including glucagon-like peptide-2 
(GLP-2), oxyntomodulin (OXM) and glicentin34. The role of PPARδ in the regulation of these hormones and 
their contribution to the phenotypes of the PPARδIEC-KO mice observed in this study, however, needs to be further 
investigated.
A role for PPARδ in Paneth cell differentiation has been described previously in PPARδ knockout mice and 
this was suggested to be associated with changes in the composition of intestinal microbiota20. In line with those 
findings we also found a reduction in the number of Paneth cells in chow fed mice but this was no longer observed 
after a HFD challenge. We also did not observe any changes in intestinal microbiota composition in PPAR δIEC-KO 
mice, suggesting that intestinal PPARδ alone is not a critical determinant in this regulation.
In addition to an increased sensitivity to diet-induced obesity, we show that PPARδIEC-KO mice are unable 
to increase plasma HDLc levels after stimulation with the PPARδ specific agonist GW501516. There is a major 
interest in therapeutic strategies that raise the levels of serum HDLc as an approach to attenuate atherosclerosis by 
promoting reverse cholesterol transport (RCT) from peripheral tissues towards the liver35. In addition to improv-
ing RCT, PPARδ activation has also been shown to reduce intestinal cholesterol absorption via downregulation of 
Niemann-Pick C1-like 1 (NPC1L1) in the intestine, which may also contribute to its potential anti-atherogenic 
effects21, 23. Agonists for all three PPARs are known to enhance HDL biogenesis and this is mediated through 
transcriptional regulation of genes involved in HDL assembly including the ATP-binding cassette transporter A1 
Figure 3. Effect of a HFD on plasma lipoprotein, plasma GLP1 and intestinal gene expression in PPARδIEC-KO 
and wild-type mice. (A,B) FPLC Lipoprotein cholesterol profiles of pooled plasma samples from PPARδIEC-KO 
mice and wild-type littermates fed a (A) LFD (n = 4–5) or (B) HFD (n = 10); Effect of a HFD challenge on (C) 
mRNA levels of proglucagon in distal small intestine (normalized to 36b4); (D) Plasma levels of Active GLP-1 
(7–36) amide and GLP-1 (7–37) in wild-type and PPARδIEC-KO mice fed a LFD (n = 4–8) or HFD (n = 10); (E,F) 
mRNA levels of genes involved in lipoprotein metabolism and inflammation in the mucosa of the distal small 
intestine of (E) wild-type and (F) PPARδIEC-KO mice (normalized to 36b4).
www.nature.com/scientificreports/
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(ABCA1) which is rate limiting in this process36. ABCA1 mediates efflux of cholesterol and phospholipid from 
cells to lipid-free apoA-I, ultimately leading to the formation of nascent HDL particles. Mice lacking ABCA1 
are unable to increase plasma HDLc in response to PPARδ activation, indicating that ABCA1 is essential in 
this process21. Approximately 70–80% of HDLc originates from the liver whereas 20–30% is produced by the 
intestine37–39. Although the ability of PPARs to increase HDL cholesterol levels has been typically attributed 
to their activation in the liver, it has recently been shown that PPARα-activation can also stimulate intestinal 
HDL-secretion ex vivo in human biopsies and Caco-2/TC7 cells40. Whether this is also the case for PPARδ, and to 
what extent the intestine contributes to the HDL-raising effects of PPAR ligands, remained unclear. Here we show 
that intestinal PPARδ is required for the stimulation of plasma HDLc levels by GW501516 and suggest that the 
role of hepatic PPARδ in HDL biogenesis is limited, at least at this dose of GW501516.
Taken together, our findings support intestinal-specific activation of PPARδ as a therapeutic approach for the 
treatment of dyslipidemia and other aspects of metabolic syndrome, while avoiding systemic toxicity.
Materials and Methods
Animals. Animals used in this study were male mice with an intestinal epithelial specific deletion of the 
PPARδ gene (PPARδIEC-KO) of a 99% C57BL/6 J genetic background between 6–16 wks of age. Mice harboring 
loxP sites on either side of exon 4 of the PPARδ gene (B6.129S4-Ppardtm1Rev/J) have been described previously31. 
To generate PPARδIEC-KO mice, PPARδlox/lox mice were crossed with transgenic mice expressing Cre recombinase 
Figure 4. Effect of PPARδ activation on cholesterol metabolism and intestinal gene expression in PPARδIEC-KO 
and wild-type mice. (A,B) FPLC Lipoprotein cholesterol profiles of pooled plasma samples from (A) wild-type 
and (B) PPARδIEC-KO mice treated with for 14 days with GW501516 or vehicle (n = 7). Plasma levels of (C) 
HDLc; and (D) Fecal neutral sterol (NS) excretion in wild-type and PPARδIEC-KO mice (n = 7) treated for 14 days 
with GW501516 (GW) or vehicle; (E,F) Levels of mRNA (normalized to 36b4) of genes involved in lipoprotein 
metabolism and inflammation in the mucosa of the small intestine of (F) wild-type and (G) PPARδIEC-KO mice 
treated for 14 days with GW501516 or vehicle (n = 7).
www.nature.com/scientificreports/
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under the control of the villin promoter which is expressed in intestinal epithelial cells (IEC). Animals were 
housed in a light- and temperature-controlled facility (lights on from 7 a.m. to 7 p.m., 21 °C) with free access to 
water and standard chow (Arie Blok, The Netherlands, No. 4063 02), semi-synthetic low fat diet (LFD, 10% kcal 
from fat) (Open Source, The Netherlands, No. D12450J) or high-fat diet (HFD, 60% kcal from fat) (Open Source 
Diets, The Netherlands, No. D12492). Animal experiments were performed with the approval of the local Ethics 
Committee for Animal Experiments of the University of Groningen. All experiments were performed in accord-
ance with relevant guidelines and regulations (including laboratory and biosafety regulations).
Animal experiments. Mice were treated with 3 mg/kg GW501516 (Alexis/Enzo Life Sciences) or vehicle 
(0.5% methylcellulose) by daily oral gavage for 14 days. Mice were anesthetized with isoflurane and euthanized 
by cardiac puncture. Terminal blood samples were collected in EDTA-coated tubes. Tissues were collected and 
frozen in liquid nitrogen or processed for histology.
Indirect calorimetry. Real-time metabolic analyses were performed using a Comprehensive Laboratory 
Animal Monitoring System (TSE systems GmbH, Bad Homburg, Germany). After a period of 24 h of acclimati-
zation, CO2 production, O2 consumption, respiratory exchange ratio (RER), food intake and activity were deter-
mined for 48 h in individual mice.
Glucose and insulin tolerance. Oral glucose tolerance tests (OGTT) were performed following oral 
administration of D-glucose at 2 g/kg body weight after a 6 h fast. Insulin tolerance tests (ITT) were performed 
following intraperitoneal (i.p.) administration of insulin (Novorapid, Novo Nordisk, Denmark) at 1 U/kg body 
weight after a 6 h fast. Blood glucose was monitored at 0, 15, 30, 60, 90 and 120 min after glucose or insulin 
administration using a OneTouch Ultra glucometer (Lifescan Inc, USA). Plasma insulin concentrations were 
determined using the ultra-sensitive mouse insulin ELISA kit from Crystal Chem (Cat. 90080, USA). Plasma 
GLP1 levels were determined following oral administration of D-glucose at 2 g/kg body weight after a 6 h fast. The 
samples were immediately treated with a DPP4 inhibitor (Merck Millipore Cat. DPP4, USA) and measured using 
the Active GLP1 Kit from MSD (ver. 2, Cat. K150JWC-1).
Fat balance. For determination of the fat balance, food intake was recorded and feces were collected over 
a period of 72 h. Fecal pellets were freeze-dried and mechanically homogenized. Lipids were extracted from the 
samples, hydrolyzed, and methylated as described previously41. The resulting fatty acid methyl esters of LCFA 
were analyzed and quantified by gas chromatography, using heptadecanoic acid as an internal standard. The fat 
absorption coefficient (%) was calculated by subtracting the fecal fat output (g/day) from the fat intake (g/day), 
divided by the fat intake (g/day) multiplied by 100%.
BA and NS analysis. Total BA and NS concentrations were determined in feces as previously described42, 43. 
Briefly, BA profiles were determined after deconjugation and extraction with commercially available Sep-Pak-C18 
(Mallinckrodt Baker, The Netherlands) cartridges and conversion to their methylester/trimethylsilyl deriv-
atives. NS in feces were saponified and extracted with hexane. BA and NS were analyzed using capillary gas 
chromatography.
Lipid and lipoprotein analysis. Pooled plasma samples were subjected to fast protein liquid chroma-
tography (FPLC) gel filtration using a Superose 6HR10/300GL column (GE Healthcare, Uppsala, Sweden) as 
described44. Individual fractions of 0,5 ml plasma diluted in PBS were analyzed for cholesterol and triglycer-
ide concentrations by spectrophotometry using commercially available kits (Roche Diagnostics, Mannheim, 
Germany). HDLc and LDLc levels in plasma were determined using a commercially available kit (Abcam, 
Cambrige, UK). Hepatic lipids were extracted according to Bligh & Dyer45. TGs were determined using the Trig/
GB (Triglycerides glycerol blanked) kit (Roche #11877771).
Gene expression analysis. Total RNA was isolated from intestinal mucosa or liver using Tri reagent (Life 
Technologies, USA) and reverse transcribed into cDNA using M-MLV, random primers and dNTPs according to 
standard procedures. For quantitative PCR (qPCR), cDNA was amplified using Hi-ROX SensiMix™ SYBR green 
(Bioline, London, UK) and StepOnePlus™ Real-Time PCR System (Applied Biosystems, CA, USA). Primers used 
for qPCR are listed in Supplementary Table 3. 36b4 was used as the house-keeping gene in all PCR analyses and 
the ∆∆Ct method was used for quantification.
Histological analysis and immunohistochemistry. For microscopic examination, tissues were fixed 
in 4% phosphate-buffered formalin, embedded in paraffin, sectioned at 4 μm, and stained with haematoxylin 
and eosin (H&E). Histological scoring was performed in an unbiased manner by two board certified veterinary 
pathologists (L.H and A.d.B.). Hepatic steatosis and inflammation were graded in H&E stained liver sections by 
using an adapted version of the NAS scoring system for NAFLD developed by Kleiner et al.46.
Analysis of microbiota. For microbiota analysis, samples were collected on chow and after treatment with 
GW501516 or HFD. The middle and distal third of the small intestine, cecum and colon including content was 
removed and homogenized in lysis buffer. Bacterial DNA from the homogenate was isolated using the QIAamp 
DNA Stool Mini Kit (Qiagen, Valencia, CA), quantified by spectrophotometry and 50 ng (15 ng respectively for 
universal bacterial primer) of DNA was amplified by RT-PCR using the SensiMix™ SYBR® Hi-ROX Kit (Bioline, 
Taunton, MA) and bacterial group-specific primers for 16S as previously described47.
Statistical analysis. Statistics were performed using the GraphPad Prism 5.00 software package (GraphPad 
Software, San Diego, CA, USA). Significance was determined using the nonparametric Mann Whitney U-test 
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when comparing two groups or the Kruskal-Wallis H-test when comparing more groups. In case of significant 
Kruskal-Wallis test, Dunns posthoc test was performed. All values are given as means ± SEM unless stated other-
wise. Significance was indicated as *P < 0.05, **P < 0.01, ***P < 0.001.
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